These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 33022187)

  • 41. Breathlessness during exercise in COPD: how do the drugs work?
    Calverley PM
    Thorax; 2004 Jun; 59(6):455-7. PubMed ID: 15170021
    [No Abstract]   [Full Text] [Related]  

  • 42. Prevalence and management of chronic breathlessness in COPD in a tertiary care center.
    Carette H; Zysman M; Morelot-Panzini C; Perrin J; Gomez E; Guillaumot A; Burgel PR; Deslee G; Surpas P; Le Rouzic O; Perez T; Chaouat A; Roche N; Chabot F;
    BMC Pulm Med; 2019 May; 19(1):95. PubMed ID: 31096982
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral transmucosal fentanyl citrate for dyspnea in terminally ill patients: an observational case series.
    Gauna AA; Kang SK; Triano ML; Swatko ER; Vanston VJ
    J Palliat Med; 2008 May; 11(4):643-8. PubMed ID: 18454622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improving dyspnea in chronic obstructive pulmonary disease: optimal treatment strategies.
    Rabe KF
    Proc Am Thorac Soc; 2006 May; 3(3):270-5. PubMed ID: 16636097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness--An Exploratory Study.
    Ferreira DH; Silva JP; Quinn S; Abernethy AP; Johnson MJ; Oxberry SG; Currow DC
    J Pain Symptom Manage; 2016 Feb; 51(2):247-54. PubMed ID: 26598037
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Exertional dyspnea in chronic obstructive pulmonary disease: mechanisms and treatment approaches.
    Ora J; Jensen D; O'Donnell DE
    Curr Opin Pulm Med; 2010 Mar; 16(2):144-9. PubMed ID: 19926997
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dyspnea as a dominant clinical manifestation in a patient with takotsubo cardiomyopathy treated for chronic obstructive pulmonary disease and hyperthyroidism.
    Biłan A; Ignatowicz A; Mosiewicz J; Wysokiński A
    Pol Arch Med Wewn; 2009 Apr; 119(4):265-8. PubMed ID: 19413188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Opioid-induced neurotoxicity.
    Gallagher R
    Can Fam Physician; 2007 Mar; 53(3):426-7. PubMed ID: 17872676
    [No Abstract]   [Full Text] [Related]  

  • 49. Palliative Care Physicians' Practice in the Titration of Parenteral Opioids for Dyspnea in Terminally Ill Cancer Patients: A Nationwide Survey.
    Mori M; Matsunuma R; Suzuki K; Matsuda Y; Watanabe H; Yamaguchi T
    J Pain Symptom Manage; 2019 Jul; 58(1):e2-e5. PubMed ID: 30999067
    [No Abstract]   [Full Text] [Related]  

  • 50. Nebulized morphine: a convenient and safe alternative to dyspnea relief?
    Baydur A
    Chest; 2004 Feb; 125(2):363-5. PubMed ID: 14769709
    [No Abstract]   [Full Text] [Related]  

  • 51. Panic, anxiety, and chronic dyspnea.
    Periyakoil VS; Skultety K; Sheikh J
    J Palliat Med; 2005 Apr; 8(2):453-9. PubMed ID: 15890059
    [No Abstract]   [Full Text] [Related]  

  • 52. It takes my breath away end-stage COPD. Part 2: pharmacologic and nonpharmacologic management of dyspnea and other symptoms.
    Dahlin C
    Home Healthc Nurse; 2006 Apr; 24(4):218-24; quiz 225-6. PubMed ID: 16680051
    [No Abstract]   [Full Text] [Related]  

  • 53. Nebulized opioids in the treatment of dyspnea.
    Quelch PC; Faulkner DE; Yun JW
    J Palliat Care; 1997; 13(3):48-52. PubMed ID: 9354041
    [No Abstract]   [Full Text] [Related]  

  • 54. Opioids in COPD: the 'whole picture' includes results from real-world, population-based observational studies.
    Vozoris NT; Gill SS; O'Donnell DE
    Br J Clin Pharmacol; 2016 Apr; 81(4):797-8. PubMed ID: 26592364
    [No Abstract]   [Full Text] [Related]  

  • 55. [The beta2-adrenergic receptor agonists in the treatment of chronic obstructive pulmonary disease].
    Chorostowska-Wynimko J
    Przegl Lek; 2005; 62(7):724-8. PubMed ID: 16463710
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death?
    Pinna MÁ
    J Palliat Med; 2013 Jan; 16(1):5. PubMed ID: 23317318
    [No Abstract]   [Full Text] [Related]  

  • 57. Management of COPD in End-of-Life Care by Spanish Pulmonologists.
    Ecenarro PS; Iguiñiz MI; Tejada SP; Malanda NM; Imizcoz MA; Marlasca LA; Navarrete BA
    COPD; 2018 Apr; 15(2):171-176. PubMed ID: 29558226
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiologies of dyspnea explained: why might opioids relieve dyspnea and not hasten death?
    Hallenbeck J
    J Palliat Med; 2012 Aug; 15(8):848-53. PubMed ID: 22594628
    [No Abstract]   [Full Text] [Related]  

  • 59. Fentanyl for dyspnea relief.
    Glass E
    Oncol Nurs Forum; 1998 Sep; 25(8):1310. PubMed ID: 9766281
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of moderate-to-severe dyspnea in hospitalized patients receiving palliative care.
    Gomutbutra P; O'Riordan DL; Pantilat SZ
    J Pain Symptom Manage; 2013 May; 45(5):885-91. PubMed ID: 22940561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.